
[EPISODE 24] Dr. David Berkowitz Talks Enzymes, Radiation, And The Lincoln Marathon
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Promising broader patient access to critical medicines, biosimilars offer a more cost-effective alternative therapeutic option compared with originator products. With
BioAgilytix adds New VP of Business Development in Europe Hamburg, Germany 01 March 2023 – BioAgilytix, a leading global bioanalytical
78,000 Square Feet of Lab and Office Space Added in the First of a Multi-Phase Expansion Durham, NC, October 19,
Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a
As therapeutic drugs have grown in complexity, so too have the bioanalysis techniques to support these products. Bioanalysis of small molecule
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Promising broader patient access to critical medicines, biosimilars offer a more cost-effective alternative therapeutic option compared with originator products. With
BioAgilytix adds New VP of Business Development in Europe Hamburg, Germany 01 March 2023 – BioAgilytix, a leading global bioanalytical
78,000 Square Feet of Lab and Office Space Added in the First of a Multi-Phase Expansion Durham, NC, October 19,
Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a
As therapeutic drugs have grown in complexity, so too have the bioanalysis techniques to support these products. Bioanalysis of small molecule
BioAgilytix employs Bio-Rad’s Luminex-based Bio-Plex Multiplex System with laser-based technology and Luminex FLEXMAP 3D® systems to run bead-based immunoassays. These platforms give us the ability to multiplex many different assays simultaneously, providing greater information from less sample volume and in a shorter timeframe than required for traditional immunoassay methods.
Based on the principles of flow cytometry, the Bio-Plex platform utilizes xMAP technology licensed from Luminex to deliver its multiplexed assay capabilities. This analyzer combines advanced fluidics, optics, and digital signal processing with Luminex’s proprietary technology to perform discrete assays on the surface of color-coded beads known as ‘microspheres’.
Built around three core technologies – the fluorescently dyed microspheres, or beads, provided from Luminex; a flow cytometer with two lasers and associated optics; and a high-speed digital processor able to efficiently manage digital output – the platform employs fluorescent methods for detection, using the bead sets to identify the analytes, and detection antibodies to measure the quantity of analyte. The use of different colored beads allows for simultaneous detection of many analytes in the same sample, and laser excitation is employed to determine analyte concentration.
The main advantages of the Luminex FLEXMAP 3D system are the ability to multiplex up to 500 analytes with minimal sample volume, and automation to support high-throughput bioassay applications.
Luminex is ideal for bioanalytical applications that require both high plex and high throughput at the same time. It is able to yield dramatically more information from rare and / or limited samples, and decipher complex interrelationships among proteins. While traditional ELISA and other technologies excel at high throughput applications – greater than 1,000 samples per day – they lack the ability to multiplex more than five tests at a time. Alternatively, microarray technology can perform high density screening – sometimes more than 250-plex tests – but cannot yield the reproducibility needed for high throughput applications.
As a flow-based system, our Luminex platforms read and quantitate bead events individually, and can perform many assays on each sample. For example, a 30-plex kit can obtain up to 3,000 data points a day on up to 100 samples. BioAgilytix most frequently uses Luminex in our work with biomarkers and cell-based assays. Our team has optimized and validated several cytokine, chemokine, growth factor, and biomarker assays ranging from known vendor protein panels (i.e., pro- or anti-inflammatory panels) to completely customized panels. We can also perform non-regulated analysis of antibodies to specific HLA haplotype expressed by allogenous cell therapy using Luminex.